RJA
LTRN icon

Raymond James & Associates’s Lantern Pharma LTRN Stock Holding History

Raymond James & Associates’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,879
Closed -$289K – 4224
2021
Q3 		$289K Buy
+25,879
New +$335K ﹤0.01% 3440

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Raymond James & Associates's LTRN Position: Q4 2021 in Review

Raymond James & Associates sold out of Lantern Pharma (LTRN) in Q4 2021, closing a stake of 25,879 shares — an estimated $289K sold.

Raymond James & Associates first reported a position in LTRN in Q3 2021 and held it in 1 quarter. The position peaked at $289K in Q3 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q4 2021.

  • Raymond James & Associates reported no remaining Lantern Pharma position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 25,879 Lantern Pharma shares in Q4 2021, an estimated $289K.
  • Raymond James & Associates first reported a position in Lantern Pharma in Q3 2021 and held it in 1 quarter.
  • Raymond James & Associates's Lantern Pharma position peaked at $289K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.